Reuters logo
BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence
September 19, 2017 / 12:43 PM / a month ago

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

Sept 19 (Reuters) - OncoMed Pharmaceuticals Inc-

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

* OncoMed Pharmaceuticals Inc - ‍Hastings will continue to be chief executive officer and chairman of board of directors during his leave of absence​

* OncoMed Pharmaceuticals Inc - ‍ in Hastings’ absence, co will be led by company’s senior management team including creation of an office of president​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below